Clinical trials: T-cell Malignancies
Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.
- Conditions
- Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
- Trial name
- NCT04554914
- Testing
- Tabelecleucel
- Where
- 40 sites in United States, Austria and 5 more
- Volunteers
- 190 people
- Sponsor
- Pierre Fabre Medicament
Relapsed or Refractory Peripheral T-Cell Lymphoma
A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T cell lymphoma.
- Trial name
- NCT04108325
- Testing
- YY-20394
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Multiple Myeloma
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT05007418
- Testing
- STI-1492
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sorrento Therapeutics, Inc.
Leukemia
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims of the study are to learn how safe GDX012 is, how treatment with GDX012 is tolerated and…
- Trial name
- NCT05886491
- Testing
- GDX012, Chemotherapy Agents
- Where
- 11 sites in United States, Japan
- Volunteers
- 16 people
- Sponsor
- Takeda
MUC17-positive Solid Tumors
Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers
To evaluate the safety and tolerability of AMG 199 in adult subjects and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
- Trial name
- NCT04117958
- Testing
- AMG 199
- Where
- 21 sites in United States, Austria and 7 more
- Volunteers
- 58 people
- Sponsor
- Amgen
Refractory Cutaneous T-cell Lymphoma
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
This is a multicenter, randomized, open-label, Phase IV study to assess the efficacy, tolerability, and safety of 2 initial dose levels of bexarotene capsules in participants with refractory CTCL.
- Trial name
- NCT01007448
- Testing
- Bexarotene
- Where
- 17 sites in United States
- Volunteers
- 59 people
- Sponsor
- Bausch Health Americas, Inc.
Metastatic Prostate Cancer
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD8359.
- Trial name
- CRIUS-1 (NCT07529717)
- Testing
- AZD8359
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Adenovirus Infection, BK Virus Infection
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
This is a Phase 3 study to evaluate posoleucel (ALVR105, Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- Prevent (NCT05305040)
- Testing
- Posoleucel (ALVR105)
- Where
- 88 sites in United States, Australia and 8 more
- Volunteers
- 451 people
- Sponsor
- AlloVir
Multiple Myeloma
Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma
This is a open-label to determine the efficacy and safety of IM21 CAR-T cells in adult with R/R multiple myeloma.
- Trial name
- NCT05478343
- Testing
- IM21 CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Small Cell Lung Cancer
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
The primary objective of the study is to provide expanded access to and characterize the safety profile of tarlatamab in participants with advanced small cell lung cancer (SCLC) after two or more prior lines of treatment…
- Trial name
- NCT06064500
- Testing
- Tarlatamab
- Where
- 23 sites in United States, Brazil and 2 more
- Sponsor
- Amgen
Acute Myeloid Leukemia, Multiple Myeloma
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma
The purpose of this first-in-man Phase I-IIa study is to evaluate the safety and antitumor activity of autologous CD44v6 CAR T-cells in patients with acute myeloid leukemia (AML) and multiple myeloma (MM).
- Trial name
- NCT04097301
- Testing
- MLM-CAR44.1 T-cells at day 0 Single intravenous infusion
- Where
- 3 sites in Czechia, Italy
- Volunteers
- 8 people
- Sponsor
- AGC Biologics S.p.A.
Myasthenia Gravis, Generalized Myasthenia Gravis
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis
- Trial name
- NCT06193889
- Testing
- Standard of Care Treatment, Standard lymphodepletion regimen, KYV-101
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 66 people
- Sponsor
- Kyverna Therapeutics
Lymphoblastic Leukemia, Acute Adult
Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
Evaluate the safety (P-I), pharmacokinetics and anti-tumor effect of immunotherapy of autologous T cells genetically modified to express anti-CD19 chimeric antigen receptor (CAR) (TBI-1501) for relapsed or refractory CD19+ B-cell…
- Trial name
- TBI-1501 (NCT03155191)
- Testing
- TBI-1501
- Where
- 11 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Takara Bio Inc.
Adult T-Cell Lymphoma (ATL)
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, and efficacy of HBI-8000 40 mg BIW in patients with relapsed or refractory ATL (R/R ATL)
- Trial name
- NCT02955589
- Testing
- HBI-8000
- Where
- 15 sites in Japan
- Volunteers
- 23 people
- Sponsor
- HUYABIO International, LLC.
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the efficacy, safety/ tolerability and pharmacokinetic of GFH009 monotherapy in patients with relapsed or refractory peripheral T-cell…
- Trial name
- NCT05934513
- Testing
- GFH009
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Adult T-cell Leukemia-lymphoma
Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma
To evaluate the efficacy, safety and pharmacokinetic profiles of KW-0761, the anti-CC chemokine receptor 4 (CCR4) antibody, when administered weekly for 8 weeks as an intravenous infusion at a dose of 1.0 mg/kg in relapsed…
- Trial name
- NCT00920790
- Testing
- KW-0761
- Where
- Japan
- Volunteers
- 28 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Large B-cell Lymphoma
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have…
- Trial name
- ALPHA3 (NCT06500273)
- Testing
- cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide
- Where
- 86 sites in United States, Australia and 2 more
- Volunteers
- 250 people
- Sponsor
- Allogene Therapeutics
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
The primary objective of this study is to compare safety and efficacy of a haploidentical T-cell depleted HSCT and adjunctive treatment with ATIR101 versus a haploidentical T cell replete HSCT with post-transplant administration…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- HATCY (NCT02999854)
- Testing
- ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor
- Where
- 42 sites in United States, Belgium and 11 more
- Volunteers
- 63 people
- Sponsor
- Kiadis Pharma
Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
The primary objective of this study is to asess the efficacy of Relmacabtagene autoleucel as second-line therapy in adult patients with aggressive B-cell Non-Hodgkins Lymphoma who are ineligible for haematopoietic stem cell…
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
- Trial name
- NCT06093841
- Testing
- Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide
- Where
- 13 sites in China
- Volunteers
- 46 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Cutaneous T-Cell Lymphoma
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
The purpose of this study is to compare the progression free survival of KW-0761 versus vorinostat for subjects with relapsed or refractory CTCL.
- Trial name
- NCT01728805
- Testing
- KW-0761, Vorinostat
- Where
- 73 sites in United States, Australia and 9 more
- Volunteers
- 372 people
- Sponsor
- Kyowa Kirin, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.